GLP-1 secretion in acute ischemic stroke: association with functional outcome and comparison with healthy individuals
Open Access
- 15 July 2019
- journal article
- research article
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 18 (1) , 1-8
Abstract
Glucagon-like peptide-1 (GLP-1) treatment has been shown to reduce stroke incidence in diabetes and also to be neuroprotective in experimental stroke models. The prognostic value of endogenous levels of GLP-1 in the recovery phase after stroke remains to be elucidated. The aim of the study was to investigate the potential association between GLP-1 levels and functional outcome after stroke and to determine whether GLP-1 is altered in the acute phase of stroke compared to 3 months post stroke and to healthy controls. Fasting GLP-1 was measured on hospital day 2–4 in patients without previously known diabetes (n = 59) that received recombinant tissue plasminogen activator (rtPA) for ischemic stroke. Fasting GLP-1 was measured again after 3 months and neurologic outcome was measured as modified Rankin Scale (mRS). mRS ≥ 2 was considered as unfavorable outcome. A control group of healthy individuals (n = 27) was recruited and their fasting GLP-1 was measured. Fasting GLP-1 was higher in the patients that suffered a stroke compared to healthy controls (25.1 vs. 18.0 pmol/L; p = 0.004). The GLP-1 levels did not change significantly at the 3-month follow up OGTT (25.8 vs. 25.6; p = 0.80). There was no significant association between GLP-1 levels and unfavorable mRS (OR 1.03, 95% CI 0.95–1.12, p = 0.50). Endogenous GLP-1 levels in patients that recently suffered an ischemic stroke are higher than in healthy controls and remained unchanged at the 3 months follow-up, possibly indicating an elevation of the levels of GLP-1 already pre-stroke. However, no association between endogenous GLP-1 and functional outcome of stroke 3 months post stroke was found.Keywords
Funding Information
- Swedish Heart and Lung Foundation (Mission Fight Stroke)
- Swedish Society for Diabetology
- European Foundation for the Study of Diabetes
- Swedish Research Council
- O. E. och Edla Johanssons Stiftelse
- STROKE Riksforbundet
- NovoNordisk Foundation
This publication has 53 references indexed in Scilit:
- The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathwayCardiovascular Diabetology, 2018
- Global Burden of StrokeSeminars in Neurology, 2018
- The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitorsCardiovascular Diabetology, 2018
- Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetesCardiovascular Diabetology, 2018
- Sex differences in the presentation of strokeMaturitas, 2017
- Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006–2013Diabetologia, 2016
- Pharmacology, Physiology, and Mechanisms of Incretin Hormone ActionCell Metabolism, 2013
- Association of Admission Blood Glucose and Outcome in Patients Treated With Intravenous ThrombolysisArchives of Neurology, 2010
- Interactions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain BarrierJournal of Molecular Neuroscience, 2002
- Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic PatientsThe Journal of Clinical Endocrinology & Metabolism, 2001